Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647443 | 0.94 | GCGR (0.67) | GCGR | |
| SCHEMBL2665676 | 0.90 | GCGR (0.62) | GCGR | |
| SCHEMBL2648956 | 0.90 | GCGR (0.47) | GCGRMAPTTDP1HPGDL3MBTL1 | |
| SCHEMBL2649721 | 0.90 | GCGR (0.62) | GCGRMAPTTDP1MEN1KMT2A | |
| SCHEMBL2647652 | 0.90 | GCGR (0.62) | GCGRMAPTTDP1MEN1KMT2A | |
| SCHEMBL2647610 | 0.89 | GCGR (0.60) | GCGRMAPTTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL2648230 | 0.87 | GCGR (0.44) | GCGRMAPTTDP1HPGDL3MBTL1 | |
| SCHEMBL2663067 | 0.87 | GCGR (0.58) | GCGRMAPTTDP1POLBALDH1A1 | |
| SCHEMBL2663070 | 0.87 | GCGR (0.58) | GCGR | |
| SCHEMBL2663071 | 0.84 | GCGR (0.55) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | claimed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |